Non Small Cell Lung Cancer

3 articles published between November 20, 2025 and September 25, 2026.

WHAT THE STUDY ACTUALLY SAYS

Adding immunotherapy to radiation did not help early-stage lung cancer survival

In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Targeted pill after surgery delays relapse in RET-driven early lung cancer

In the phase 3 LIBRETTO-432 trial, adjuvant selpercatinib raised two-year event-free survival to 92% from 61% in resected stage II-IIIA RET fusion-positive lung cancer. The trial was small and survival is unproven.

4 min read

THE DRUG DOCKET

A second oral HER2 lung-cancer drug clears FDA on tumour response, not survival

Hyrnuo (sevabertinib) is cleared for previously treated HER2-mutant NSCLC on response rate alone. The confirmatory trial that must justify it does not report until 2029.

4 min read

This page indexes this newspaper’s reporting on Non Small Cell Lung Cancer. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.